Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Korea Venture Fund, OrbiMed Co-lead Series A Financing For South Korean mAb Developer PharmAbcine

This article was originally published in The Pink Sheet Daily

Executive Summary

The financing is a first where a Korean start-up was able to attract an international syndicate of this stature, OrbiMed Caduceus Asia Partners Managing Director Chang said

You may also be interested in...

Novartis To Sell Flu Vaccine Adjuvant To Korea's Green Cross

SEOUL - South Korean vaccine maker Green Cross recently signed a deal with Novartis to buy the latter's adjuvanted A/H1N1 vaccine MF59 to expand Green Cross' A/H1N1 vaccine production volume

Biotech, Small Pharma IPO Market Frozen For At Least Next Year, VCs Say – Bio Korea

OSONG, South Korea - The worldwide market for biotech and other pharmaceutical companies seeking funds through initial public offers is closed for at least a year and other sources of money are becoming scarce as well, venture capital firms said during the annual Bio Korea conference in Osong, South Korea

Life Sciences Investors Talk Shop On Asia Opportunities – Singapore Conference

SINGAPORE - The swing from big pharma to biotech has captured investor attention, and has changed the nature of the types of investments that venture capitalists are making. Many are willing to take bigger risks in Asia and are opting in earlier rather than as pipelines mature, making intellectual property protection even more critical, a panel of investors said during the BioMedical Asia 2008 conference in Singapore April 15





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts